NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product ...
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding ...
Tiziana Life Sciences is following biotech’s third-quarter cull trend, though it’s attempting to do so more covertly, putting several of its pipeline programs on the shelf in a “near-term focus” ...
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against other ...
Tiziana Life Sciences, Ltd. has announced the publication of a review article in Nature Reviews Neurology, which highlights the potential of its lead drug candidate, intranasal foralumab, for treating ...
Tiziana Life Sciences Ltd.’s stock TLSA soared 54% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug Administration for its investigational new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results